Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact
Attralus logo
  • Home
  • Company
    • About
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Investors
  • Science
    • Approach
    • PAR Therapeutics
  • Pipeline
  • News
    • Press Releases
    • Posters & Publications
  • Amyloidosis
  • Careers
  • Contact
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Imaging Candidates at ASNC 2025

Attralus Presents New Data on Its Pan-Amyloid Diagnostic Imaging Candidates at ASNC 2025

Sep 8, 2025 Press Releases

PDF Version 124I-evuzamitide, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected of or diagnosed with cardiac amyloidosis in ATTR, AL, and other rare types of...
Attralus Presents New Data on Its Pan-Amyloid Diagnostic Imaging Candidates at ASNC 2025

Attralus Presents New Data on Its Pan-Amyloid Diagnostic Candidates at the 2025 American College of Cardiology (ACC) Annual Scientific Session

Apr 1, 2025 Press Releases

PDF Version 124I-evuzamitide (AT-01) PET/CT, the first pan-amyloid diagnostic imaging agent, demonstrated 100% sensitivity and specificity for the diagnosis of cardiac amyloidosis in patients suspected or diagnosed with cardiac amyloidosis in ATTR, AL, and other rare...

Detection Of Cardiac Amyloidosis, and More, Using SPECT/CT Imaging of Technetium-99m-Labeled Peptide P5+14 (At-05)

Mar 31, 2025 Posters & Publications

Click Here to View...

Preliminary Evaluation of 99mTc-Labeled Peptide p5+14 (AT-05) for the Detection of Cardiopulmonary Amyloidosis Using SPECT/CT and Planar Gamma Scintigraphic Imaging

May 28, 2024 Posters & Publications

Click Here to View...

Recent Posts

  • Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis
  • Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis
  • Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus
  • Renal and cardiac responses in a phase 1/2 study of AT-02, a novel pan-amyloid depleter IgG fusion protein for the treatment of patients with AL amyloidosis
  • Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

Recent Comments

No comments to show.
COMPANY
About
Management Team
Board of Directors
Scientific Advisory Board
Investors

SCIENCE
Approach
PAR Therapeutics

PIPELINE

NEWS
Press Releases
Posters & Publications

AMYLOIDOSIS
CAREERS
CONTACT

  • Privacy Policy
  • Terms of Service
  • Follow
  • Follow
Attralus logo

Attralus, Inc.
365 Fifth Ave South, Ste 208
Naples, FL 34102

©2026 Attralus, Inc.  All Rights Reserved.